• Miscellaneous immune disorders

Revcovi Generic Name & Formulations

General Description

Elapegademase-lvlr 2.4mg/1.5mL; soln for IM inj; preservative free.

Pharmacological Class

Recombinant adenosine deaminase.

How Supplied

Single-dose vial—1

Generic Availability


Revcovi Indications


Treatment of adenosine deaminase severe combined immune deficiency (ADA-SCID).

Revcovi Dosage and Administration

Adults and Children

Individualize. Adjust dose based on trough ADA activity, trough dAXP levels, and/or patient's clinical status (see full labeling). Give as IM inj; rotate sites. Transitioning from Adagen (weekly Adagen dose ≤30 U/kg or unknown): initially 0.2mg/kg once weekly; (weekly Adagen dose >30 U/kg): calculate dose using conversion formula (Revcovi dose [mg/kg] = Adagen dose [U/kg]/150). May increase subsequent doses in 0.033mg/kg increments weekly based on appropriate trough levels. Adagen-naive: initially 0.4mg/kg weekly (based on ideal body weight) divided into 2 doses (0.2mg/kg twice weekly) for at least 12–24 weeks until immune reconstitution achieved. May gradually decrease dose to maintain appropriate trough levels and/or adequate immune reconstitution.

Revcovi Contraindications

Not Applicable

Revcovi Boxed Warnings

Not Applicable

Revcovi Warnings/Precautions


Determine trough plasma ADA activity and trough dATP level prior to first administration. After initiation, measure trough plasma ADA activity (pre-injection) every 2 weeks (Adagen-naive) or 4 weeks (Adagen-experienced), during first 8–12 weeks of treatment, then every 3–6 months thereafter. Adjust dose if persistent fall in trough plasma ADA activity due to antibodies development. Monitor trough erythrocyte dAXP levels at least twice a year after 2 months of treatment. Monitor lymphocytes every 4–8 weeks for up to 1 year, and every 3–6 months thereafter (Adagen-naive), or every 3–6 months (others). Thrombocytopenia; do not initiate if severe. Protect immune deficient patients from infections until immune function improved. Elderly (≥65yrs): not studied. Pregnancy: monitor closely. Nursing mothers.

Revcovi Pharmacokinetics

See Literature

Revcovi Interactions

Not Applicable

Revcovi Adverse Reactions

Adverse Reactions

Cough, vomiting; possible immunogenicity.

Revcovi Clinical Trials

See Literature

Revcovi Note

Not Applicable

Revcovi Patient Counseling

See Literature